Market Access UCB brings first therapy for rare disease TK2d to EU PharmaphorumThe EU has approved UCB's Kygevvi for rare disease TK2d, and Sanofi's acute GvHD therapy Rezurock, in a pair of decisions announced this morning.Market AccessRare DiseaseRead full story pharminent March 31, 2026 (Last updated: March 31, 2026) Pharmaphorum The EU has approved UCB’s Kygevvi for rare disease TK2d, and Sanofi’s acute GvHD therapy Rezurock, in a pair of decisions announced this morning. Market AccessRare DiseaseRead full story Post navigation Previous: Drug Channels News Roundup, March 2026: Cigna’s 340B Workaround, Merck’s ARPA Surprise, Walgreens’ Automation Bet, Why Rebates Hurt Patients, and a DCI Team PhotoNext: Merck strikes deal with antibody discovery startup Related Stories Market Access Deal finally unlocks NHS access to ITF’s Duchenne drug pharminent May 11, 2026 Market Access Specialty Pharmacy Accreditation: DCI’s Exclusive Analysis Reveals a Market at an Inflection Point pharminent May 5, 2026 Market Access Where Gross-to-net Pressure Actually Lives After Launch pharminent May 1, 2026
